help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Watanabe, R. M.
Right arrow Articles by Bergman, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watanabe, R. M.
Right arrow Articles by Bergman, R. N.

Journal of Clinical Endocrinology & Metabolism, Vol 79, 1277-1283, Copyright © 1994 by Endocrine Society


ARTICLES

Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors

RM Watanabe, CG Azen, S Roy, JA Perlman and RN Bergman
Department of Exercise Science, University of Southern California School of Medicine, Los Angeles 90033.

We performed oral glucose tolerance tests and frequently sampled iv glucose tolerance tests in a cross-sectional sample of women taking monophasic norgestrel containing oral contraceptives (OC). The goal of the study was to quantify the individual factors that determine glucose tolerance to assess responsibility for the reduced glucose tolerance associated with the use of OCs. Subjects were selected using stringent criteria to exclude confounding effects of ethnicity, adiposity, or conditions that may predispose subjects to metabolic disorders. Users of the low dose OC (Lo/Ovral and Nordette) and high dose OC (Ovral) were compared to controls, who were required to never have used OCs or to have discontinued OC use for at least 24 months. Oral glucose tolerance tests results confirmed the development of impaired glucose tolerance in both pill groups. Frequently sampled iv glucose tolerance test data were analyzed using the minimal model method to estimate parameters of insulin sensitivity, glucose effectiveness (SG), and beta- cell function. Lo/Ovral users had lower insulin sensitivity and SG compared to controls and inappropriately low beta-cell function in relation to the insulin resistance. Ovral users had metabolic parameters that were not different from controls. Based upon comparisons between normal and impaired glucose tolerant subjects combined with stepwise regression analysis, we conclude that Lo/Ovral use results in insulin and glucose resistance, which is not compensated by increased beta-cell function. The reduced glucose tolerance is due primarily to the defect in SG, and these OC users may place themselves at higher risk for the development of diabetes or cardiovascular disease. The reduced tolerance in Ovral users cannot be explained by the parameters measured in this study. We speculate that these latter subjects represent a special self-selected population in which tolerance is regulated by other factors. Ovral appears to be well tolerated by these women.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
B. A. Frempong, M. Ricks, S. Sen, and A. E. Sumner
Effect of Low-Dose Oral Contraceptives on Metabolic Risk Factors in African-American Women
J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2097 - 2103.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
J. Vrbikova and D. Cibula
Combined oral contraceptives in the treatment of polycystic ovary syndrome
Hum. Reprod. Update, May 1, 2005; 11(3): 277 - 291.
[Abstract] [Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
D. C. Henderson, E. Cagliero, P. M. Copeland, C. P. Borba, E. Evins, D. Hayden, M. T. Weber, E. J. Anderson, D. B. Allison, T. B. Daley, et al.
Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis
Arch Gen Psychiatry, January 1, 2005; 62(1): 19 - 28.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
M. E. Doyle and J. M. Egan
Pharmacological Agents That Directly Modulate Insulin Secretion
Pharmacol. Rev., March 1, 2003; 55(1): 105 - 131.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
K. Elter, G. Imir, and F. Durmusoglu
Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study
Hum. Reprod., July 1, 2002; 17(7): 1729 - 1737.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Nader, M. G. Riad-Gabriel, and M. F. Saad
The Effect of a Desogestrel-Containing Oral Contraceptive on Glucose Tolerance and Leptin Concentrations in Hyperandrogenic Women
J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3074 - 3077.
[Abstract] [Full Text] [PDF]


Home page
The Diabetes EducatorHome page
J. Betschart
Oral Contraception and Adolescent Women With Insulin-Dependent Diabetes Mellitus: Risks, Benefits, and Implications for Practice
The Diabetes Educator, January 1, 1996; 22(4): 374 - 378.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1994 by The Endocrine Society